Table 1  Demographic characteristics of liver transplant recipient with SARS-CoV-2 infection
Study population  Results
Patients, n  57
Sex, male, n (%)  40 (70)
Ethnicity, Caucasian, n (%)  53 (93)
Age, years, median (IQR)  65 (57–70)
 Age ≥65, n (%)  29 (51)
 Age <65, n (%)  28 (49)
BMI, kg/m2, mean (SD)  26.0±4.6
BMI, classes, n (%)   
 18–24.9  23 (43)
 25–29.9  23 (43)
 >30  8 (14)
Time from transplant to diagnosis, years, median (IQR)  6 (2–13)
 Very long-term transplant recipients, n (%)   21 (37)
 Very short-term transplant recipients, n (%)  11 (19)
 Long-term transplant recipients, n (%)  32 (56)
Indication to LT, n (%)   
 End-stage liver disease  38 (68)
 Liver tumour  16 (29)
 Acute liver failure  4 (7)
 Other  9 (16)
Underlying liver disease, n (%)   
 ALD  15 (26)
 Viral  24 (42)
  HCV  11 (19)
  HBV  13 (23)
 PSC  3 (5)
 PBC  4 (7)
 NAFLD/NASH  2 (4)
 Autoimmune  1 (2)
 Hemochromatosis  1 (2)
 Wilson’s disease  1 (2)
 Other  10 (18)
HCC, yes, n (%)  20 (35)
Comorbidities, n (%)   
 Cardiovascular disease  21 (37)
  Coronary artery disease  7 (12)
  Heart failure  9 (16)
  Atrial fibrillation  6 (11)
  Stroke  1 (2)
  Other  8 (14)
  >1 cardiovascular disease  10 (18)
 Arterial hypertension  32 (56)
 Diabetes mellitus  21 (37)
 Active cancer  5 (9)
 Kidney insufficiency  16 (28)
 Respiratory disease  13 (23)
  COPD  7 (12)
  HIV  1 (2)
Smoke history, yes, n (%)  7 (12)
Symptoms at presentation, n (%)   
 Fever  44 (79)
 Cough  31 (55)
 Dyspnoea  26 (46)
 Fatigue and myalgia  32 (56)
 GI symptoms  18 (33)
  Diarrhoea  16 (28)
  Abdominal pain  1 (2)
  Vomiting  1 (2)
 Anosmia or dysgeusia  4 (7)
 Other  8 (14)
Concomitant bacterial infection, n (%)  9 (16)
 Suspected  3 (6)
 Confirmed  6 (11)
ALD, alcoholic liver disease; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HCC, hepatocellular carcinoma; LT, liver transplantation; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.